Table 2.
Patient characteristics.
|
|
Total (n=794) | LNMa status | P value | |||
|
|
|
pN2b (n=105) | pN0c or pN1d (n=689) |
|
||
| Age (years), mean (SD) | 60.92 (51.48 to 70.36) | 60.87 (51.87 to 69.86) | 60.93 (51.42 to 70.44) | .45 | ||
| Sex, n (%) | —e | — | — | .06 | ||
|
|
Male | 397 | 62 | 335 | — | |
|
|
Female | 397 | 43 | 354 | — | |
| Smoking history, n (%) | — | — | — | .04 | ||
|
|
Yes | 337 | 55 | 282 | — | |
|
|
No | 457 | 50 | 407 | — | |
| Drinking history, n (%) | — | — | — | .94 | ||
|
|
Yes | 183 | 25 | 158 | — | |
|
|
No | 611 | 80 | 531 | — | |
| Family history, n (%) | — | — | — | .32 | ||
|
|
Yes | 137 | 14 | 123 | — | |
|
|
No | 657 | 91 | 566 | — | |
| Hypertension, n (%) | — | — | — | .18 | ||
|
|
Yes | 232 | 37 | 195 | — | |
|
|
No | 562 | 68 | 494 | — | |
| Diabetes, n (%) | — | — | — | .25 | ||
|
|
Yes | 84 | 15 | 69 | — | |
|
|
No | 710 | 90 | 620 | — | |
| Pulmonary tuberculosis, n (%) | — | — | — | .33 | ||
|
|
Yes | 33 | 2 | 31 | — | |
|
|
No | 761 | 103 | 658 | — | |
| Cardiovascular disease, n (%) | — | — | — | .06 | ||
|
|
Yes | 36 | 9 | 27 | — | |
|
|
No | 758 | 96 | 662 | — | |
| Cerebrovascular disease, n (%) | — | — | — | .35 | ||
|
|
Yes | 29 | 6 | 23 | — | |
|
|
No | 765 | 99 | 666 | — | |
| Tumor locationf, n (%) | — | — | — | .22 | ||
|
|
RULg | 249 | 27 | 222 | — | |
|
|
RMLh | 59 | 4 | 55 | — | |
|
|
RLLi | 150 | 18 | 132 | — | |
|
|
LULj | 185 | 31 | 154 | — | |
|
|
LLLk | 126 | 21 | 105 | — | |
|
|
Other | 25 | 4 | 21 | — | |
| TLAf,l, median (IQR) | 2.61 (1.20 to 4.01) | 3.02 (1.64 to 4.39) | 2.55 (1.15 to 3.94) | <.001 | ||
| TSAf,m, median (IQR) | 2.03 (0.88 to 3.18) | 2.38 (1.27 to 3.48) | 1.98 (0.83 to 3.13) | <.001 | ||
| Spiculationf, n (%) | — | — | — | .08 | ||
|
|
Yes | 255 | 42 | 213 | — | |
|
|
No | 539 | 63 | 476 | — | |
| Lobulationf, n (%) | — | — | — | <.001 | ||
|
|
Yes | 211 | 48 | 163 | — | |
|
|
No | 583 | 57 | 526 | — | |
| Tumor densityf, n (%) | — | — | — | <.001 | ||
|
|
pGGOn | 124 | 0 | 124 | — | |
|
|
mGGOo | 96 | 3 | 93 | — | |
|
|
Solid nodule | 574 | 102 | 472 | — | |
| Vessel invasionf, n (%) | — | — | — | .87 | ||
|
|
Yes | 52 | 6 | 46 | — | |
|
|
No | 742 | 99 | 643 | — | |
| Pleural indentationf, n (%) | — | — | — | .001 | ||
|
|
Yes | 406 | 70 | 336 | — | |
|
|
No | 388 | 35 | 353 | — | |
| HLNLAf,p, n (%) | — | — | — | .008 | ||
|
|
>10 mm | 148 | 30 | 118 | — | |
|
|
≤10 mm | 646 | 75 | 571 | — | |
| HLNSAf,q, n (%) | — | — | — | <.001 | ||
|
|
>10 mm | 66 | 19 | 47 | — | |
|
|
≤10 mm | 728 | 86 | 642 | — | |
| MLNLAf,r, n (%) | — | — | — | <.001 | ||
|
|
>10 mm | 191 | 50 | 141 | — | |
|
|
≤10 mm | 603 | 55 | 548 | — | |
| MLNSAf,s, n (%) | — | — | — | <.001 | ||
|
|
>10 mm | 72 | 27 | 45 | — | |
|
|
≤10 mm | 722 | 78 | 644 | — | |
| CEAt, median (IQR) | 5.31 (–6.66 to 17.27) | 12.66 (–8.44 to 33.76) | 4.18 (–5.17 to 13.54) | <.001 | ||
| CA199u, median (IQR) | 14.41 (–3.24 to 32.06) | 15.80 (–5.08 to 36.68) | 14.20 (–2.90 to 31.29) | .47 | ||
| CA125v, median (IQR) | 14.46 (0.03 to 28.90) | 19.88 (–5.56 to 45.32) | 13.64 (1.96 to 25.32) | <.001 | ||
| NSEw, median (IQR) | 15.81 (8.85 to 22.78) | 16.26 (10.19 to 22.33) | 15.75 (8.66 to 22.83) | .048 | ||
| Cyfra211x, median (IQR) | 3.20 (–0.23 to 6.62) | 3.55 (–0.64 to 7.75) | 3.14 (–0.15 to 6.43) | .06 | ||
| SCCAgy, median (IQR) | 0.96 (–0.16 to 2.08) | 1.18 (–0.62 to 2.99) | 0.93 (–0.04 to 1.90) | .14 | ||
aLNM: lymph node metastasis.
bpN2: pathological N stage 2.
cpN0: pathological N stage 0.
dpN1: pathological N stage 1.
eNot applicable.
fFeatures recorded in computed tomography reports.
gRUL: right upper lobe.
hRML: right middle lobe.
iRLL: right lower lobe.
jLUL: left upper lobe.
kLLL: left lower lobe.
lTLA: tumor long axis.
mTSA: tumor short axis
npGGO: pure ground glass opacity.
omGGO: mixed ground glass opacity.
pHLNLA: hilar lymph node long axis.
qHLNSA: hilar lymph node short axis.
rMLNLA: mediastinal lymph node long axis.
sMLNSA: mediastinal lymph node short axis.
tCEA: carcinoembryonic antigen.
uCA199: carbohydrate antigen 19-9.
vCA125: carbohydrate antigen 12-5.
wNSA: neuron-specific enolase.
xCyfra211: cytokeratin 19-fragments.
ySCCAg: squamous cell carcinoma antigen.